secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0000950170-25-082697
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences elects Tiba Aynechi and Kent Hawryluk as Class I directors; Carl Gordon departs board
--------------------------------------------------------------------------------

- Stockholders elected Tiba Aynechi (24.3M for) and P. Kent Hawryluk (24.4M for) to three-year terms ending 2028.
- Carl L. Gordon, Ph.D., CFA departed the board effective June 5, 2025; his term ended at the annual meeting.
- Ratification of Ernst & Young as independent auditor for FY2025 passed with 27.8M for, 3,467 against.
- Annual meeting held June 5, 2025; 33.4M shares outstanding as of April 11 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025082697/0000950170-25-082697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025082697/mbx-20250605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-082697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer